ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,625Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 208

$1.53M Total Retail Price of All Prescriptions

Rank: 5 out of 208

1,136 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
35% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

1% of this provider’s 1,136 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 10,228 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

49% of this provider’s prescriptions were for brand-name drugs, compared to an average of 51%.

Prescription Price

$112 was the average price of a prescription from this provider, compared to $143 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
SYNTHROID 1,394 1,113 1 2
LEVOTHYROXINE SODIUM 1,233 882 2 1
GLIMEPIRIDE 686 560 3 10
PEN NEEDLE 632 504 10 4 3
METFORMIN HCL 610 446 5 4
INSULIN SYRINGE 511 410 6 9
SIMVASTATIN 374 307 7 6
METHIMAZOLE 372 329 8 17
LEVOXYL 345 234 9 16
LANTUS 320 220 10 7
HUMALOG 307 219 11 8
ATORVASTATIN CALCIUM 296 234 12 15
METFORMIN HCL ER 277 182 13 13
LEVEMIR FLEXPEN 237 185 14 19
NOVOLOG 212 131 15 18
JANUVIA 197 181 16 12
PRAVASTATIN SODIUM 197 159 16 27
LANTUS SOLOSTAR 190 158 18 5
HUMALOG MIX 75-25 172 128 19 25
ZETIA 170 88 20 30
NOVOLOG FLEXPEN 165 135 21 11
NOVOLOG MIX 70-30 FLEXPEN 146 143 22 21
LEVEMIR 145 114 23 55
POTASSIUM CHLORIDE 143 114 24 54
JANUMET 140 98 25 28
LISINOPRIL 132 87 26 14
CRESTOR 122 86 27 31
LIPITOR 113 80 28 67
LOSARTAN POTASSIUM 110 90 29 34
HYDROCHLOROTHIAZIDE 110 83 29 29
HUMULIN R 109 60 31 46
LOVAZA 109 40 31 39
NOVOLOG MIX 70-30 108 78 33 83
ACTOS 101 92 34 22
HUMULIN N 99 66 35 26
NATEGLINIDE 94 87 36 56
AMLODIPINE BESYLATE 80 58 37 20
ZEMPLAR 69 69 38 128
DIOVAN 69 38 38 42
CALCITRIOL 69 43 38 119
ULTRA COMFORT 68 34 41 176
NOVOLIN N 63 36 42 57
FENOFIBRATE 62 49 43 43
LOSARTAN-HYDROCHLOROTHIAZIDE 60 44 44 106
ANDROGEL 57 18 S3 45 60
GABAPENTIN 56 40 46 38
PREDNISONE 55 40 47 93
SENSIPAR 55 55 47 108
OMEPRAZOLE 54 28 49 36
KLOR-CON 10 52 41 50 118
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 13, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.